Researchers at the University of Michigan Rogel Cancer Center have made a significant breakthrough in understanding why some prostate cancers become increasingly aggressive and resistant to standard therapies. In a study published in the Journal of Clinical Investigation, a team led by Dr. Zhi Duan and senior study author Dr. Joshi J. Alumkal identified a specific gene, PROX1, that plays a pivotal role in driving prostate cancer cells to transition into more lethal, treatment-resistant forms. This discovery offers a promising new therapeutic path, suggesting that an existing class of drugs may be effective in treating patients who currently face limited options.

The challenge of managing advanced prostate cancer often hinges on "lineage plasticity," a biological process through which cancer cells evolve to bypass the standard treatments that initially keep them in check. Most prostate cancers rely on the androgen receptor (AR) to grow and survive. Consequently, the primary standard of care for advanced prostate cancer typically involves androgen deprivation therapy, which aims to block the activity of this receptor. However, the study highlights a critical hurdle: many tumors eventually stop relying on the androgen receptor altogether, rendering these traditional treatments ineffective.

"Patients whose prostate tumors lose reliance on the androgen receptor do poorly," explained Dr. Joshi J. Alumkal, the Wicha Family Professor of Oncology at the University of Michigan Rogel Cancer Center. "Our results suggest a therapeutic approach for patients whose tumors have undergone that shift."

This transition away from androgen receptor dependence is not an abrupt event but rather a continuum. As cancer cells undergo lineage plasticity, they essentially "switch" their identity, shedding the traits that made them susceptible to standard therapies and adopting alternate, more aggressive identities. To uncover the mechanisms behind this shift, the research team analyzed patient tumor biopsies to determine which factors might be triggering this change. Their findings pointed directly to the PROX1 gene, which serves as a master regulator of cell identity in both healthy and cancerous tissue.

The team’s investigation revealed that as prostate cancer cells begin their transition to an alternate identity, the expression of PROX1 increases significantly. By examining hundreds of patient tumor samples across various stages of lineage plasticity, the researchers confirmed that PROX1 functions as an early marker of this dangerous transition. Specifically, they found that tumors classified as "double-negative prostate cancer"—which lack both androgen receptor activity and other common markers—as well as "neuroendocrine prostate cancer," a highly aggressive form of the disease, consistently turned on the PROX1 gene.

The relationship between PROX1 and the androgen receptor appears to be antagonistic. In their analysis of patient tumor datasets, the researchers observed that when PROX1 levels were high, androgen receptor levels were consistently low. Further experiments in the laboratory confirmed this link: when the team forced the expression of PROX1 in prostate cancer cells, the cells subsequently shut down their androgen receptor production.

"We think PROX1 is regulating the androgen receptor," Dr. Alumkal noted. "It may be one explanation for why the androgen receptor gets turned off when tumors undergo lineage plasticity and transition away from the typical glandular prostate cancer identity."

Recognizing PROX1 as a key driver of this aggressive transformation provided the team with a clear target. When the researchers used genetic methods to eliminate PROX1 expression in laboratory models of double-negative and neuroendocrine prostate cancer, the results were striking: the cancer cells stopped proliferating and began to die. This indicated that if clinicians could inhibit the function of PROX1, they might be able to halt or reverse the growth of these stubborn tumors.

However, targeting PROX1 directly presented a classic challenge in molecular oncology. PROX1 is a transcription factor, a type of protein that acts like a switch to turn genes on or off. Because of their complex, internal structures, transcription factors are historically notoriously difficult to "drug" or inhibit with conventional small-molecule therapies. Faced with this barrier, the research team sought a workaround by looking at the proteins that interact with PROX1.

By analyzing the "company" that PROX1 keeps within the cellular environment, the researchers identified histone deacetylases, or HDACs, as top binding partners for the PROX1 protein. "We felt like this was guilt by association," Dr. Alumkal said. "We hypothesized that HDACs might cooperate with PROX1 and that targeting HDACs might be like targeting PROX1."

This hypothesis proved successful. HDACs are already recognized as significant players in various cancer types, and a number of HDAC inhibitors have already received approval from the U.S. Food and Drug Administration for use in other oncology contexts. When the team treated PROX1-expressing prostate cancer cells with these existing HDAC inhibitors, the cells proved highly sensitive to the drugs. The treatment effectively depleted the PROX1 protein, leading to the death of the tumor cells—a result that mirrored the impact of genetically removing the gene entirely.

These findings suggest that HDAC inhibitors, which are already available in the clinical arsenal, could be repurposed to combat aggressive subtypes of prostate cancer that have escaped standard androgen-targeted therapies. By blocking the activity of PROX1 via its partners, physicians may be able to offer a new line of defense to patients who have exhausted current treatment options.

"Our work implicates PROX1 as an important early driver away from androgen receptor dependence," Dr. Alumkal stated. "HDAC inhibitors can block PROX1 and reduce survival of aggressive prostate tumor models that have transitioned away from androgen receptor reliance. Our results suggest this class of drugs should be prioritized for clinical trials in patients who have aggressive prostate cancer subtypes, for which there are few treatment options."

The research team, which included an extensive list of collaborators such as Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, and many others, has opened a door that could lead to significant improvements in clinical outcomes for patients with treatment-resistant disease. The study was supported by a wide array of funding organizations, including the National Institutes of Health, the U.S. Department of Defense, the Prostate Cancer Foundation, the Canadian Institutes of Health Research, and several other private and public foundations.

As the scientific community moves forward, the focus will likely shift toward translating these laboratory successes into clinical trials. By identifying the molecular drivers of lineage plasticity and leveraging existing drug classes to intercept them, this research provides a roadmap for addressing one of the most difficult challenges in modern prostate cancer care. The ability to "catch" these tumors as they undergo their transition, and to use targeted inhibition to stop their progression, remains a vital goal for future oncological research.